Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan
This article was originally published in The Pink Sheet Daily
Executive Summary
EU marketing partnership brings Myriad considerable royalties and milestones if compound wins approval as first drug to delay Alzheimer’s progression.